EZH2 and breast cancer: Agilent microarrays were used to perform gene expression profiling in MDA-MB-231 breast cancer cells after 24 h of treatment with the hit compound HKMTI-1-005, the EZH2 inhibitor GSK343 [10] and EHMT2 inhibitor UNC0638 [22].